Brief: Sino Biopharmaceutical Says Envonalkib (TQ-B3139) Got Approval For Marketing From Nmpa Of China
19/06/2024 11:09
June 19 (Reuters) - Sino Biopharmaceutical Ltd
1177.HK :
* ENVONALKIB (TQ-B3139) OBTAINED APPROVAL FOR MARKETING
FROM NMPA
OF CHINA
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up